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Ibis Reproductive Health aims to improve access to medication abortion for 
women around the world. Using clinical and social science research, we test 
ways to make protocols and regimens—including both mifepristone and 
misoprostol and misoprostol-alone options—more user friendly; explore 
ways to improve access to medication abortion services and service delivery; 
and examine global policy related to medication abortion. We also strive to 
improve access to medication abortion by providing medically accurate 
information about this service to diverse audiences. We work in many 
different contexts, including where abortion is legal and where it is restricted, 
low-resource settings, and places where rates of unsafe abortion are high.  
Review of the evidence for making medication 
abortion more user friendly 
Mifepristone and misoprostol medication abortion was originally 
approved as a three-visit regimen in settings where abortion is 
legal, with the first visit to assess the woman’s eligibility and 
dispense mifepristone, the second visit to administer misoprostol, 
and the third visit to confirm that the abortion was complete and 
rule out complications. Researchers have been examining ways to 
simplify the regimen so it is easier for women to access.  
With colleagues from Gynuity Health Projects and the Department 
of Family and Social Medicine of the Montefiore Medical Center/
Albert Einstein College of Medicine, Ibis reviewed the evidence on 
ways to simplify medication abortion provision and outlined areas 
for further research. Research has clearly shown the effectiveness 
of a two-visit strategy, which gives women the option of taking 
misoprostol at home instead of at the clinic, and this approach has 
largely become standard of care. The review covered a number of 
other modifications designed to streamline service delivery, lower 
cost, and increase access to care while maintaining high levels of 
safety, efficacy, and acceptability. The following regimen and 
protocol improvements are supported by research evidence, but 
not yet incorporated into standard of care: 
■ Clinical exam in combination with a woman’s report of her 
last menstrual period can be safely substituted for routine 
ultrasound when determining gestational age before 
medication abortion, assuming that there are no discrepancies 
between the woman’s report and the bimanual examination. 
■ Serial serum hCG measures can be substituted for routine 
ultrasound when confirming termination of pregnancy and 
ruling out rare conditions such as ectopic pregnancy and 
gestational trophoblastic disease.  
Additional modifications, such as self-assessment of eligibility for 
abortion and alternatives for post-abortion follow-up (including 
alternatives to ultrasound or blood tests in a clinic setting and self-
assessment for follow-up care), have the potential to further 
increase the accessibility of medication abortion for women but 
require further research. See the article Can mifepristone medical 
abortion be simplified? A review of the evidence and questions for future 
research by Clark et al. 2007 for more information.  
Highlights 
 Current evidence supports simplifying 
medication abortion protocols and regimens to 
make them more user friendly. 
 Ibis has evaluated innovations including self-
assessment of gestational age before abortion 
and urine pregnancy tests to verify successful 
termination of pregnancy. 
Eliminating the need for routine ultrasound 
before medication abortion  
Routine use of ultrasound examination for determination of 
pregnancy duration limits women’s access to medication abortion 
by restricting provision of the method to facilities with ultrasound 
equipment. Eliminating the need for this procedure before a 
woman can receive a medication abortion could increase access, 
particularly in low-resource settings. Here we highlight two of 
Ibis’s studies which examine the possibility of replacing ultrasound 
with women’s or providers’ estimates of gestational age before 
medication abortion and find promising results. 
Evaluation of women’s and clinicians’ estimates of 
gestational age 
In South Africa, access to reproductive health care is included in 
the Constitution and abortion is permitted up to 20 weeks without 
restriction; nurses and midwives provide most abortions up to 12 
weeks gestation. Mifepristone is approved for early abortion up to 
56 days from the last menstrual period (LMP). As part of a study 
on women’s and providers’ attitudes towards medication abortion 
conducted in collaboration with colleagues at Gynuity Health 
Projects, the Philadelphia Hospital in Mpumalanga, the Population 
Council, the Reproductive Health and HIV Research Unit of the 
University of Witwaterstrand in Soweto, and the Women’s Health 
Research Unit of the University of Cape Town, we collected data 
on women’s, providers’, and ultrasound assessments of gestational 
age and analyzed results from more than 600 abortion clients. We 
calculated women’s and providers’ estimates in three ways: clinical 
exam, women’s report of LMP, and women’s estimation of 
pregnancy duration. Estimates of duration of pregnancy based on 
Where we work 
Ibis works in a number of countries in 
diverse contexts, including in Latin 
America and the Caribbean, the Middle 
East and North Africa, sub-Saharan 
Africa, and the United States. In this 
brief, we feature work completed in 
Mexico and South Africa.  
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Ciencias Medicas y Nutrición Salvador Zubirán, the Instituto 
Nacional de Perinatología Isidro Espinosa de los Reyes, and the 
Population Council, we evaluated a urine dipstick pregnancy test 
with four possible outcomes [negative, hCG<1000 IU/L, 
hCG>1000 IU/L (indicating ongoing pregnancy), or 
indeterminate] with 97 women at a hospital and private clinic in 
Mexico and compared its accuracy to serum hCG measurements 
from blood tests. We found the test to be reasonably accurate; 
sensitivity (ability to correctly identify ongoing pregnancies) was 
88.6% and specificity (ability to correctly identify women without 
ongoing pregnancies) was 71.7%. Further work is needed to refine 
the test and testing algorithm and to determine sensitivity in 
settings where the less effective misoprostol-alone regimen is used, 
but the test shows promise as a way to screen for ongoing 
pregnancy after medication abortion. More information is available 
in the article Accuracy of a semi-quantitative urine pregnancy test compared 
to serum beta-hCG measurement: A possible screening tool for ongoing 
pregnancy after medication abortion by Grossman et al. 2007. 
Systematic review of alternatives to ultrasound for follow-up 
after medication abortion 
We conducted a systematic review of alternative ways to diagnose 
ongoing pregnancies after first-trimester medication abortion. Our 
search identified eight articles that compared two or more follow-
up modalities, including women’s self-assessment, clinicians’ 
assessment, serum hCG measurements, urine pregnancy tests, and 
combinations of the above. The most promising modalities 
included serum hCG measurements, standardized assessment of 
women’s symptoms combined with low-sensitivity urine pregnancy 
testing, and standardized telephone consultation (perhaps followed 
by high-sensitivity urine pregnancy test). These follow-up 
modalities were highly accurate at identifying ongoing pregnancies 
(the proportions of women with ongoing pregnancies who were 
correctly identified were all ≥90%, and the proportions of women 
who tested negative who did not have an ongoing pregnancy were 
all ≥99%). Furthermore, the proportions of women who were 
diagnosed with ongoing pregnancy by the follow-up modality and 
would therefore be referred for further evaluation, such as by 
ultrasound, were low, ≤33%. Additional research is needed to 
demonstrate the accuracy, acceptability, and feasibility of these 
alternative follow-up modalities in practice, in particular of home-
based urine testing combined with self-assessment and/or  
clinician-assisted assessment. However, these findings indicate that 
alternatives to routine ultrasound after medication abortion are 
accurate at diagnosing ongoing pregnancy. More information is 
available in the article Alternatives to ultrasound for follow-up after 
medication abortion: A systematic review by Grossman and Grindlay 
2010. 
clinical exams were, on average, only two days different 
than ultrasound estimates, a clinically insignificant 
difference. A small proportion of women, approximately 
10%, would have been identified as eligible for medication 
abortion based on a clinical exam, but were not eligible 
based on ultrasound findings. It is important to note that as 
gestational age increases additional counseling and support 
are needed to manage the side effects, but efficacy does not 
drop off precipitously at the cut-off so the majority of these 
women could likely have safely used medication abortion. Using a 
clinical exam to determine eligibility for medication abortion could 
greatly expand access to the method in South Africa, and we are 
currently working with advocates and policymakers to change 
guidelines and practice to use clinical exam as the main way to 
determine eligibility with ultrasound on referral if needed. More 
information on the study is available in the article A comparison of 
women’s, providers’ and ultrasound assessments of pregnancy duration among 
termination of pregnancy clients in South Africa by Blanchard et al. 2007. 
Evaluation of a pregnancy wheel tool 
In Mexico, where abortion is highly restricted except in the capital 
city and where many women self-medicate with misoprostol to 
terminate pregnancies, we worked with the Population Council 
Mexico to pilot test a pregnancy-wheel tool that women can use to 
estimate their gestational age and suitability for abortion in the first 
trimester. Use of this tool would not only make medication 
abortion less onerous by eliminating the need for pre-abortion 
ultrasound, but would also make it safer for women in legally 
restricted and resource-poor settings by giving women who choose 
to self-medicate a reliable way to determine their eligibility for 
medication abortion. 
Eliminating the need for routine ultrasound after 
medication abortion 
Routine follow-up visits after medication abortion are 
recommended or required by most medication abortion protocols, 
primarily to diagnose ongoing pregnancies. Although pelvic 
ultrasonography is not required by the United States Food and 
Drug Administration-approved mifepristone label, many health 
care facilities employ it to detect ongoing pregnancy. Here we 
highlight two of Ibis’s projects that examine alternative ways to 
identify ongoing pregnancies after medication abortion, and 
suggest ways to further increase access to medication abortion.  
Evaluation of a semi-quantitative urine pregnancy test in 
settings where ultrasound equipment is not available 
Levels of hCG decline in the body after pregnancy and serum 
hCG measurements from blood tests can be used as an alternative 
to ultrasound to verify successful termination of pregnancy in a 
clinic setting. Use of a urine pregnancy test to measure hCG levels 
and detect ongoing pregnancy would further simplify medication 
abortion. With collaborators from the Instituto Nacional de 
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